Fundraising FoxVivo Capital — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.
BiotechHealthtechMedical DevicesSan Diego, US
Marc Nasoff(Chief Scientific Officer)
BoardJay B. Lichter(Ph.D.)in
Co-investorsLilly Asia VenturesAvalon BioVenturesOUP (Osage University Partners)
BiotechSanta Clara, US
Jeffrey Glenn(Director)David Cory(Executive Officer, Director)
BoardNina Kjellson(Director)inEd Engleman(Director)
Board seatEdgar G. Engleman· per SEC Form D · $3M raise · filed Apr 2016
Co-investorsPfizer Venture InvestmentsCanaan PartnersVivo Ventures
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardVictor Tong(Director)Thomas Grogan(Director)
Board seatYuh-geng Tsay· per SEC Form D
Co-investorsDecheng CapitalLAVLilly Asia VenturesLilly VenturesPavilion Capital
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
BiotechMedical DevicesPalo Alto, US
Xiaoling Charlene Liao(Executive Officer, Director)Charlene Liao(Founder)in
BoardGuo-Liang Yu(Director)Liqun Luo(Director)
Co-investorsCLI VenturesNorthern Light Venture CapitalShangBay Capital LLCStartXTriWise Capital
SentreHeart appears to now redirect to AtriCure, Inc., a medical device company.
BiotechHardwareHealthtechMedical DevicesRedwood City, US
Russell Seiber(Executive Officer, Director)inPam Simons(Executive Officer)inGreg Fung(Executive Officer)Robert Strasser(Executive Officer)in
BoardPhil Young(Director)inVictor Tong(Director)
Co-investorsDecheng CapitalProspect Venture PartnersUS Venture PartnersDeerfield Management CompanyU.S. Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.